# OnCo record trastuzumab-pamirtecan (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/trastuzumab-pamirtecan/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "trastuzumab-pamirtecan" ;
  schema:name "Trastuzumab pamirtecan"@en ;
  schema:alternateName "BNT323"@en ;
  schema:description "Trastuzumab pamirtecan is DualityBio and BioNTech's HER2 antibody-drug conjugate, in phase 3 trials in breast cancers with high and with modest HER2 expression and in HER2-expressing endometrial cancer."@en ;
  schema:url <https://onco.cc/drugs/trastuzumab-pamirtecan/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=DB-1303> ;
  onco:status "phase-3" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Antibody-drug conjugate (anti-HER2 antibody, topoisomerase I inhibitor payload)" ;
  onco:cancers <https://onco.cc/cancers/breast-her2-positive/>, <https://onco.cc/cancers/endometrial/> ;
  onco:technologies <https://onco.cc/technologies/adc/> ;
  onco:targets <https://onco.cc/targets/her2/> ;
  onco:companies <https://onco.cc/companies/dualitybio/>, <https://onco.cc/companies/biontech/> ;
  onco:trials <https://onco.cc/trials/nct06265428/>, <https://onco.cc/trials/nct06018337/>, <https://onco.cc/trials/nct06340568/>, <https://onco.cc/trials/nct06827236/>, <https://onco.cc/trials/nct05150691/> .